Simon, T. G., Henson, J. B., Osganian, S., Kaplan, A., Masia, R., Chung, R. T., … Corey, K. E. (2018). Long-Term Aspirin Use and Risk for Fibrosis Progression, in a Prospective Population with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease (NAFLD). In HEPATOLOGY (Vol. 68, pp. 967A-967A).

Simon, Tracey G., Jacqueline B. Henson, Stephanie Osganian, Alyson Kaplan, Ricard Masia, Raymond T. Chung, Andrew Chan, and Kathleen E. Corey. “Long-Term Aspirin Use and Risk for Fibrosis Progression, in a Prospective Population with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease (NAFLD).” In HEPATOLOGY, 68:967A-967A, 2018.

Simon TG, Henson JB, Osganian S, Kaplan A, Masia R, Chung RT, et al. Long-Term Aspirin Use and Risk for Fibrosis Progression, in a Prospective Population with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease (NAFLD). In: HEPATOLOGY. 2018. p. 967A-967A.

Simon, Tracey G., et al. “Long-Term Aspirin Use and Risk for Fibrosis Progression, in a Prospective Population with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease (NAFLD).” HEPATOLOGY, vol. 68, 2018, pp. 967A-967A.

Simon TG, Henson JB, Osganian S, Kaplan A, Masia R, Chung RT, Chan A, Corey KE. Long-Term Aspirin Use and Risk for Fibrosis Progression, in a Prospective Population with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease (NAFLD). HEPATOLOGY. 2018. p. 967A-967A.